课题基金 / 基金详情

Preclinical approach to improve testing of immuno-oncology combination therapies for early or late stage metastatic disease

Preclinical approach to improve testing of immuno-oncology combination therapies for early or late stage metastatic disease
改善早期或晚期转移性疾病免疫肿瘤联合疗法测试的临床前方法
批准号：
344284
负责人：
Kerbel Robert S
金额：
$44.28万
依托单位：
Sunnybrook Research Institute (Toronto, Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2016
资助国家：
加拿大
项目状态：
已结题
起止时间：
2016-03-01 至 2021-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=344284&lang=en
关键词：
Adjuvant Therapy Animal Models Chemotherapy - General Experimental Therapeutics Imaging Immune Checkpoint Inhibitors Immuno-Oncology Metastatic Therapy Metronomic Chemotherapy Tumor Angiogenesis

项目摘要

项目成果

Kerbel Robert S的其他基金

相似基金

相关文献

中文摘要
翻译
建议的计划有两个主要的互补目标。一种是利用自化疗发现以来最有希望的癌症治疗发展：利用人体免疫系统能力的新药的影响
英文摘要
The proposed Project Scheme has two major complementary aims. One is designed to leverage what is the most promising development in cancer therapy since the discovery of chemotherapy: the impact of new drugs which harness the body's immune system ability
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Low Dose Metronomic Chemotherapy as a Combination Strategy to Combat Innate or Acquired Resistance to Immune Checkpoint Therapy
Translational studies of acquired resistance to antiangiogenic therapies undertaken in new preclinical models of locally advanced or metastatic cancer
海外基金